Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely

Immune checkpoint blockade with PD-(L)1 antibodies has revolutionized the treatment of advanced non–small cell lung cancer (NSCLC). Similarly, the identification and targeting of oncogene drivers i...